| Yazarlar |
Özcan Başaran
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
|
Volkan Doğan
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
|
Kadir Uğur Mert
Eskişehir Osmangazi Üniversitesi, Türkiye |
|
Bülent Özlek
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
|
Eda Özlek
Türkiye |
|
Oğuzhan Çelik
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
|
Cem Çil
Türkiye |
|
İbrahim Halil Özdemir
Türkiye |
Prof. Dr. İbrahim RENCÜZOĞULLARI
Kafkas Üniversitesi, Türkiye |
|
Fatma Özpamuk Karadeniz
Karamanoğlu Mehmetbey Üniversitesi, Türkiye |
|
Mehmet Tekinalp
Türkiye |
|
Lütfü Aşkın
Gaziantep İslam Bilim ve Teknoloji Üniversitesi, Türkiye |
|
Selami Demirelli
Sağlık Bilimleri Üniversitesi, Türkiye |
|
Erkan Gencer
|
|
Lütfü Bekar
Hitit Üniversitesi, Türkiye |
|
Müjdat Aktaş
Türkiye |
|
Mübariz Murat Resulzade
|
|
Macit Kalçık
Hitit Üniversitesi, Türkiye |
|
Gökhan Aksan
Türkiye |
|
Göksel Çinier
Sağlık Bilimleri Üniversitesi, Türkiye |
|
Kadriye Halli Akay
|
|
Nihat Pekel
Türkiye |
|
Gurbet Özge Mert
Eskişehir Osmangazi Üniversitesi, Türkiye |
|
Utku Şenol
Türkiye |
|
Vahit Demir
Türkiye |
|
Sinan İnci
Türkiye |
|
Emir Derviş
Türkiye |
|
Murat Biteker
Türkiye |
|
Latife Meral Kayıkçıoğlu
Ege Üniversitesi, Türkiye |
| Özet |
| Background: The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Methods: Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. Results: This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on highintensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target <55 mg/dL could only be achieved in 2.2% and 8.1% of very high-risk primary prevention and secondary prevention patients, respectively. Conclusion: The control of dyslipidemia was extremely poor among patients with diabetes. The use of lipid-lowering treatment was not at the desired level, and high-intensity lipid-lowering treatment use was even lower. Our simulation model showed that the highdose statin plus ezetimibe therapy would improve goal attainment; however, it would not be possible to get goals with this treatment in more than one-third of the patients. |
| Anahtar Kelimeler |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
| Dergi Adı | Kare Publishing |
| Dergi ISSN | 2149-2263 |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Dergi Grubu | Q3 |
| Makale Dili | İngilizce |
| Basım Tarihi | 02-2023 |
| Cilt No | 27 |
| Sayı | 2 |
| Sayfalar | 78 / 87 |
| Doi Numarası | 10.14744/AnatolJCardiol.2022.2012 |
| Makale Linki | http://dx.doi.org/10.14744/anatoljcardiol.2022.2012 |
